關(guān)鍵詞

布地奈德 非酒精性脂肪性肝炎 ABCWY疫苗 西米普利單抗 單細(xì)胞多組學(xué)分析 托萊西單抗 艾貝司他 福雷蘆單抗

?

#今日行業(yè)熱點(diǎn)#

①The Lancet：Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial

臨床試驗(yàn)：布地奈德靶向釋放制劑用于原發(fā)性IgA腎病患者的療效和安全性(NefIgArd):一項(xiàng)Ⅲ期、多中心、隨機(jī)、雙盲、安慰劑對(duì)照試驗(yàn)

DOI: 10.1016/S0140-6736(23)01554-4

②The Lancet Gastroenterology and Hepatology：NASH drug treatment development: challenges and lessons

綜述：非酒精性脂肪性肝炎（NASH）藥物研發(fā)的歷程、教訓(xùn)與挑戰(zhàn)

DOI: 10.1016/S2468-1253(23)00159-0

③The Lancet Infectious Diseases：Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial

臨床試驗(yàn)：五價(jià)腦膜炎球菌ABCWY疫苗在青少年和年輕人中的免疫原性和安全性：一項(xiàng)觀察者盲、主動(dòng)對(duì)照、隨機(jī)試驗(yàn)

DOI: 10.1016/S1473-3099(23)00191-3

④The Lancet Oncology：First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial

臨床試驗(yàn)：PD-1抑制劑西米普利單抗（Cemiplimab）單藥及聯(lián)合化療用于具有高PD-L1表達(dá)（TPS≥50％）、局部晚期或轉(zhuǎn)移性的非小細(xì)胞肺癌（NSCLC）的隨訪（EMPOWER-Lung 1）：一項(xiàng)多中心、開放標(biāo)簽、隨機(jī)、Ⅲ期試驗(yàn)

DOI: 10.1016/S1470-2045(23)00329-7

⑤The Lancet Respiratory Medicine：Pulmonary hypertension associated with lung disease: new insights into pathomechanisms, diagnosis, and management

綜述：對(duì)與肺部疾病相關(guān)的肺動(dòng)脈高壓的病理機(jī)制、診斷和管理的新見解

DOI: 10.1016/S2213-2600(23)00259-X

⑥Nature Immunology：Single-cell multiomic analysis of thymocyte development reveals drivers of CD4+ T cell and CD8+ T cell lineage commitment

胸腺細(xì)胞發(fā)育的單細(xì)胞多組學(xué)分析揭示CD4+ T細(xì)胞和CD8+ T細(xì)胞譜系分化的驅(qū)動(dòng)因素

DOI: 10.1038/s41590-023-01584-0

⑦國產(chǎn)首款自主研發(fā)的抗PCSK9單克隆抗體托萊西單抗獲得國家藥品監(jiān)督管理局批準(zhǔn)用于原發(fā)性高膽固醇血癥和混合型血脂異常的成人患者

⑧泛HDAC抑制劑艾貝司他聯(lián)合替莫唑胺在美國針對(duì)復(fù)發(fā)性膠質(zhì)瘤（GBM）的Ⅰ期臨床首個(gè)劑量組給藥和初步安全性評(píng)估進(jìn)展順利，將開始更高劑量組的患者入組

⑨靶向cadherin-6（CDH6）抗體偶聯(lián)藥物（ADC）CUSP06獲FDA批準(zhǔn)開展Ⅰ期臨床，擬評(píng)估用于鉑類難治/耐藥卵巢癌和其他晚期實(shí)體瘤

⑩靶向CD3的全人源單克隆抗體福雷蘆單抗（Foralumab）獲FDA批準(zhǔn)臨床，用于阿爾茲海默癥

科學(xué)探索的世界充滿挑戰(zhàn)，AtaGenix致敬每一位拓荒者，更致力于成為您信賴的合作伙伴！